Next up is Joshua Thurman with a lot review of GN 
first study is BLISS-LN. Mentions that 2 years of infusions in 448 patients is a big lift. Points out they changed the outcome (probably listens to @NephJC_Podcast (nephjc.com/freelyfiltered…) #AspenKidney
Her is underwelmed with the magnitude of the effect size. He is not sure how to use it. #AspenKidney
Next up AURORA-1 Voclosporin. Felt it also had a marginal benefit. #AspenKidney
Next is membrnaous. Talking MENTOR. Points out that stopping the CNI means people will relapse. #AspenKidney
STARMEN Trial. He was surprised by the good showing of Modified Ponticelli Protocol. #AspenKidney
On to PEXIVAS Trial of plasmapheresis in ANCA Associated Vasculitis.
No benefit to plasma exchange
No cost to lower dose steroids
No benefit to plasma exchange
No cost to lower dose steroids
He doesn't like to change management based on one study but he is skeptical that we will ever see a better study. #AspenKidney
On to ADVOCATE Study of Avacapan in vasculitis. Avacapan is a C5 inhibitor. #AspenKidney
Next is IgA nephropathy shared long term (10 year) follow-up of STOP-IgA. Still no advantage to steroids. #AspenKidney
Finishes up with DAPA-CKD and pointing out the non-diabetic data. #AspenKidney
Good showing by #NephJC. @NephJC covered every study he highlighted except the long term follow-up of STOP-IgA. #AspenKidney
And join us tonight as we discuss LANDMARK study of lanthanum v calcium binders.
And join us tonight as we discuss LANDMARK study of lanthanum v calcium binders.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
